HCC podcast series part 1: The use of IO in unresectable HCC

November 21, 2024 • 00:23:21
HCC podcast series part 1: The use of IO in unresectable HCC
COR2ED - Oncology Medical Conversation
HCC podcast series part 1: The use of IO in unresectable HCC

Nov 21 2024 | 00:23:21

/

Show Notes

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include: 

 

 

Key clinical takeaways:

 

 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

 

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. 

 

This podcast is developed by cor2ed.com 

Published on November 2024 

 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Other Episodes

Episode

December 06, 2023 • 00:24:54
Episode Cover

Advanced HCC: Patients not eligible for IO - What are the treatment options?

Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David...

Listen

Episode

October 15, 2026 • 00:27:28
Episode Cover

Metastatic TNBC cannot wait

In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic...

Listen

Episode

December 06, 2023 • 00:21:28
Episode Cover

Precision oncology: Detection and treatment of TRK fusion-positive lung cancers

In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology...

Listen